Back to our people pageBack to Locations

Ben Enejo

Partner

Ben assists top healthcare clients across Regulatory & Medical Affairs functions, as well as Commercial Strategy & Operations, with a specialty in business transformation and operational excellence initiatives.

Ben Enejo | ADLITTLE

Areas of Focus

Education

Cranfield School of Management
Master of Business Administration
Cranfield University
M.Sc. Molecular Medicine
Nottingham Trent University
B.Sc. Physiology & Pharmacology

Past Experience

PA Consulting Group
Healthcare Management Consultant
Astra Zeneca
Patient Safety Advisor
Janssen Pharmaceuticals (Johnson & Johnson)
Pharmacovigilance Associate
Medical Gases Ltd
Sales Engineer (Business Development)

Ben Enejo | ADLITTLE

Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.

Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.

Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
 

Why patient centricity is key to long-term pharma company success
Healthcare & life sciences
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
Find out more
The future of pharmacovigilance
Healthcare & life sciences
The future of pharmacovigilance
Ben Enejo
While assessing the safety and efficacy of medicines is the bedrock in drug research, vaccine development during the COVID-19 pandemic highlighted the changes in the types of medicines developed today and the stakeholder management required for successful adoption. Enabled by new treatment paradigms, digital transformation, advanced technology applications, data availability, and the patient-centric focus, the changing ecosystem requires new capabilities in assessing the safety of medicines and managing the new entities at play.
Find out more
Healthcare & life sciences
Elixir of the afterlife
Emmanuel Aisabokhae, Ben Enejo
Find out more

Ben Enejo | ADLITTLE

Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.

Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.

Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
 

Why patient centricity is key to long-term pharma company success
Healthcare & life sciences
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
Find out more
The future of pharmacovigilance
Healthcare & life sciences
The future of pharmacovigilance
Ben Enejo
While assessing the safety and efficacy of medicines is the bedrock in drug research, vaccine development during the COVID-19 pandemic highlighted the changes in the types of medicines developed today and the stakeholder management required for successful adoption. Enabled by new treatment paradigms, digital transformation, advanced technology applications, data availability, and the patient-centric focus, the changing ecosystem requires new capabilities in assessing the safety of medicines and managing the new entities at play.
Find out more
Healthcare & life sciences
Elixir of the afterlife
Emmanuel Aisabokhae, Ben Enejo
Find out more

More About Ben
  • Cranfield School of Management
    Master of Business Administration
  • Cranfield University
    M.Sc. Molecular Medicine
  • Nottingham Trent University
    B.Sc. Physiology & Pharmacology
  • PA Consulting Group
    Healthcare Management Consultant
  • Astra Zeneca
    Patient Safety Advisor
  • Janssen Pharmaceuticals (Johnson & Johnson)
    Pharmacovigilance Associate
  • Medical Gases Ltd
    Sales Engineer (Business Development)